Top-Rated StocksTop-RatedNASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free AXSM Stock Alerts $75.64 -0.04 (-0.05%) (As of 09:57 AM ET) Add Compare Share Share Today's Range$75.26▼$76.2050-Day Range$65.72▼$82.4252-Week Range$55.02▼$98.40Volume22,045 shsAverage Volume703,677 shsMarket Capitalization$3.59 billionP/E RatioN/ADividend YieldN/APrice Target$121.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Axsome Therapeutics alerts: Email Address Axsome Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside61.1% Upside$121.92 Price TargetShort InterestBearish16.32% of Shares Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.25Based on 33 Articles This WeekInsider TradingSelling Shares$3.99 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.75) to $0.68 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.46 out of 5 starsMedical Sector106th out of 905 stocksPharmaceutical Preparations Industry36th out of 422 stocks 4.5 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Axsome Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.32% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Axsome Therapeutics has recently increased by 1.31%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 1.8 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Axsome Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 18 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,994,220.00 in company stock.Percentage Held by Insiders24.50% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axsome Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($3.75) to $0.68 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -14.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -14.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 18.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axsome Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Axsome Therapeutics Stock (NASDAQ:AXSM)Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More AXSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXSM Stock News HeadlinesMay 9, 2024 | americanbankingnews.comLeerink Partnrs Comments on Axsome Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:AXSM)May 8, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical TrialsMay 9, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.May 8, 2024 | globenewswire.comAxsome Therapeutics to Present at Upcoming Investor ConferencesMay 8, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Given Buy Rating at HC WainwrightMay 8, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $112.00 at Robert W. BairdMay 8, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $125.00 by Analysts at CitigroupMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed on Axsome Therapeutics Amid Strong Sales and Strategic PositioningMay 9, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.May 7, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call TranscriptMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion PotentialMay 7, 2024 | finance.yahoo.comAxsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ...May 7, 2024 | finance.yahoo.comQ1 2024 Axsome Therapeutics Inc Earnings CallMay 6, 2024 | fool.comAxsome Therapeutics (AXSM) Q1 2024 Earnings Call TranscriptMay 6, 2024 | investorplace.comAXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | washingtonpost.comAxsome: Q1 Earnings SnapshotMay 6, 2024 | msn.comAxsome Therapeutics GAAP EPS of -$1.44 misses by $0.21, revenue of $75M beats by $2.15MMay 6, 2024 | globenewswire.comAxsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | stocknews.comInvestors Beware of These 3 Pharma StocksMay 1, 2024 | globenewswire.comAxsome Therapeutics Recognizes May as Mental Health Awareness MonthApril 30, 2024 | investorplace.com3 Biotech Stocks with Blockbuster Drug Pipelines: April EditionApril 30, 2024 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Upgraded to Overweight by Morgan StanleyApril 29, 2024 | finance.yahoo.comGinkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of DirectorsApril 29, 2024 | markets.businessinsider.comBuy Rating on Axsome Therapeutics Amidst Strong Auvelity Performance and Positive Revenue ProspectsApril 29, 2024 | msn.comAxsome Therapeutics stock rises on upgrade to Overweight at Morgan StanleyApril 29, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring Axsome Therapeutics Through Analyst InsightsApril 29, 2024 | americanbankingnews.comAxsome Therapeutics (AXSM) Scheduled to Post Quarterly Earnings on MondaySee More Headlines Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today5/09/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees545Year FoundedN/APrice Target and Rating Average Stock Price Target$121.92 High Stock Price Target$190.00 Low Stock Price Target$81.00 Potential Upside/Downside+61.1%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($5.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-239,240,000.00 Net Margins-88.41% Pretax Margin-88.06% Return on Equity-70.67% Return on Assets-27.47% Debt Debt-to-Equity Ratio0.93 Current Ratio3.63 Quick Ratio3.52 Sales & Book Value Annual Sales$270.60 million Price / Sales13.28 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book18.73Miscellaneous Outstanding Shares47,490,000Free Float35,857,000Market Cap$3.59 billion OptionableOptionable Beta1.13 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Herriot Tabuteau M.D. (Age 56)Founder, Chairman, CEO & President Comp: $1.32MMr. Hunter Murdock Esq. (Age 44)General Counsel & Secretary Comp: $735.39kKey CompetitorsBiohavenNYSE:BHVNSummit TherapeuticsNASDAQ:SMMTCrinetics PharmaceuticalsNASDAQ:CRNXUltragenyx PharmaceuticalNASDAQ:RAREPrestige Consumer HealthcareNYSE:PBHView All CompetitorsInsiders & InstitutionsState Board of Administration of Florida Retirement SystemSold 620 shares on 5/9/2024Ownership: 0.020%US Bancorp DESold 9,919 shares on 5/8/2024Ownership: 0.281%ProShare Advisors LLCBought 800 shares on 5/8/2024Ownership: 0.020%Russell Investments Group Ltd.Bought 777 shares on 5/8/2024Ownership: 0.002%Sei Investments Co.Bought 2,697 shares on 5/7/2024Ownership: 0.075%View All Insider TransactionsView All Institutional Transactions AXSM Stock Analysis - Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks. What is Axsome Therapeutics' stock price target for 2024? 13 brokers have issued 12-month price objectives for Axsome Therapeutics' stock. Their AXSM share price targets range from $81.00 to $190.00. On average, they anticipate the company's stock price to reach $121.92 in the next twelve months. This suggests a possible upside of 61.1% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts. How have AXSM shares performed in 2024? Axsome Therapeutics' stock was trading at $79.59 on January 1st, 2024. Since then, AXSM stock has decreased by 4.9% and is now trading at $75.68. View the best growth stocks for 2024 here. When is Axsome Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our AXSM earnings forecast. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its earnings results on Tuesday, February, 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.21) by $0.48. The business earned $71.53 million during the quarter, compared to analyst estimates of $70.38 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 70.67% and a negative net margin of 88.41%. What ETFs hold Axsome Therapeutics' stock? ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include US Bancorp DE (0.28%), Iridian Asset Management LLC CT (0.27%), WCM Investment Management LLC (0.24%), Peregrine Capital Management LLC (0.18%), Lindbrook Capital LLC (0.18%) and BNP Paribas Financial Markets (0.17%). Insiders that own company stock include Mark Coleman, Mark E Saad, Mark L Jacobson, Nick Pizzie and Roger Jeffs. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXSM) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.